Controlled clinical trials for treating schizophrenia often involve selected patients with common characteristics. It is recognized that schizophrenia patients are much more diverse than those in the clinical setting, and that physicians' prescribing practices may vary. The objective of the study is to examine treatment practices for adult schizophrenic patients by their own physicians, and to assess patient outcomes when treated with long-acting risperidone injection. This is a 2-year, prospective, multi-center, longitudinal, observational study in adults with schizophrenia. Physicians will determine the appropriate treatment for their patients, according to their usual practice. Patients starting treatment with long-acting risperidone injection and meeting all the study criteria may enroll in the study. They will be administered a dose of 25, 37.5 or 50 mg of risperidone every 2 weeks by intramuscular injection, and continue their treatment for schizophrenia according to usual care by their physicians. Patients will be asked questions at baseline and every three months for a period of two years to assess: efficacy of the medication, how well the patient is functioning, use of healthcare resources (e.g., emergency room visits, hospitalizations) patient work status, quality of life and patient satisfaction with the medicine. Safety will be monitored throughout the study.

A dose of 25, 37.5 or 50 mg of risperidone, administered every 2 weeks by intramuscular injection. The study duration is 2 years.